IgG Glyco-Engineering to Improve IVIg Potency

@article{Bruggeman2018IgGGT,
  title={IgG Glyco-Engineering to Improve IVIg Potency},
  author={Christine W Bruggeman and Gillian Dekkers and Remco Visser and Naneth W. M. Goes and Timo K van den Berg and Theo Rispens and Gestur Vidarsson and Taco W Kuijpers},
  journal={Frontiers in immunology},
  year={2018},
  volume={9},
  pages={
          2442
        }
}
Intravenous immunoglobulins (IVIg) are used in the treatment of different autoimmune and inflammatory diseases, such as immune thrombocytopenia and hemolytic anemia. One of the modes of action of IVIg is preventing phagocytosis of autoantibody-opsonized blood cells by saturation of the Fc-gamma receptors of macrophages in spleen and liver. IgG contains a fixed glycan, which is in most cases biantennary, at the asparagine residue at position 297 in the Fc tail. This glycan consists of a core… CONTINUE READING